Case Study: Cutting Review Time, Accelerating Pharma Submissions

Introduction: Why Review Bottlenecks Cost Pharma Millions In pharma, every day counts. Review delays on clinical data or regulatory dossiers can derail approvals, push back launches, and erode market trust. In pharma, inconsistency isn’t just an inconvenience — it risks EMA/FDA rejections, rework, and millions in lost revenue. Enterprises need workflows engineered for speed without regulatory risk. Client Overview Client Type: Global Pharmaceutical Manufacturer Sector: Life Sciences, Regulatory Affairs Geography: North America & EU markets Client Size: Fortune 500 pharma company with operations in 30+ markets Project Scope & Timeline: Translation of 1,200+ pages of clinical and regulatory documentation under 6-week deadline Challenges Faced Challenge Why It Matters Slow review cycles (average 3+ weeks per batch) Delayed regulatory submissions risked losing market exclusivity windows Terminology inconsistencies Increased risk of rejection by health authorities (FDA/EMA) Limited reviewer bandwidth Medical reviewers bogged down in repetitive corrections, diverting from core work Linear workflows (hand-offs between translators, reviewers, and QA) Prolonged TAT, no parallel efficiency Near-miss moment: In one submission, dosage terminology inconsistencies triggered a week-long back-and-forth with internal reviewers. The client risked missing their EMA filing deadline — a delay that could have cost tens of millions in lost first-to-market advantage. Source : Case Study: Cutting Review Time, Accelerating Pharma Submissions

Comments

Popular posts from this blog

Linguistic Challenges in Japanese Localization

Do’s & Don’ts: 6 Fonts That Break Arabic and Thai Layouts